The National Academies of Sciences Report: Hepatitis B and C Elimination

 
 
Share this
 
 

Background

The National Academies of Sciences, Engineering, and Medicine are private, nonprofit institutions that provide independent, objective analysis and advice to the nation and conduct other activities to solve complex problems and inform public policy decisions related to science, technology, and medicine.

Many of the studies the Academies undertake are requested by federal agencies and independent organizations; others begin as specific mandates from Congress. The Academies also convene a series of forums, roundtables, and standing committees to facilitate discussion, discovery, and cross-disciplinary thinking.

Note: The National Academies of Sciences, Engineering, and Medicine Health and Medicine Division was previously called the Institute of Medicine (IOM).

Overview: A National Strategy for the Elimination of Hepatitis B and C

The National Academies of Sciences, Engineering, and Medicine’s (NAS) Committee on a National Strategy for the Elimination of Hepatitis B & C is exploring the elimination of hepatitis B and C from the United States in two phases. First, it considered the feasibility of elimination as a goal, with attention to social and logistical aspects of feasibility as well as scientific ones. The Phase One report was released in April 2016. In Phase Two, the committee will lay out a strategy to reach the goals identified in the first report. The Phase Two report will give attention to likely obstacles to elimination and ways to overcome them. In this report the committee will recommend actions to specific stakeholders, with some attention to the role of correctional facilities, primary care, and community health centers.

NVHR is pleased to be a sponsor of the second phase of work by NAS, along with the Centers for Disease Control and Prevention's Division of Viral Hepatitis, the Office of Minority Health, the Division of Cancer Prevention and Control within CDC, the American Association for the Study of Liver Disease, and the Infectious Diseases Society of America. The study is closely aligned with our mission of fighting, and ultimately ending, the hepatitis B and C epidemics in the United States. We believe the final recommendations will provide the necessary call to action to achieve elimination goals.

Phase I Report: Eliminating the Public Health Problem of Hepatitis B and C in the United States

On April 11, 2016, the National Academies of Sciences, Engineering, and Medicine's Health and Medicine Division released its Phase One report Eliminating the Public Health Problem of Hepatitis B and C in the U.S. This report explores the barriers that must be overcome to eliminate hepatitis B and C in the United States. The report reaffirms that hepatitis B and C elimination can be achieved with sufficient resources, commitment, and strategies. NAS also announced that it will now enter Phase Two of this process.

The NAS Phase One report is available here.

Coming Soon: Phase II Report

The Phase 2 report from the committee will be released in the spring of 2017.

In Phase 2, the NAS’ Committee on a National Strategy for the Elimination of Hepatitis B & C will develop a consensus report that is expected to be released in the first half of 2017 and will include specific recommendations and targets for elimination. The committee’s consensus report will identify:

  1. The appropriate hepatitis reduction or elimination goal(s) and specifying a plan of action to achieve the goal(s) including: medical and substance abuse services, community-based services, and correctional health services.
  2. Barriers to achieving the goal(s) such as access to treatment and related policy issues, public health infrastructure resources for screening, education and outreach, and surveillance.
  3. Potential solutions to the barriers identified.
  4. Specific stakeholders and their responsibilities to achieve the goal.

Phase II Meeting: National Strategy on the Elimination of Hepatitis B & C

This meeting of the National Academies of Sciences’ (NAS) Committee on a National Strategy for the Elimination of Hepatitis B & C took place from June 8-9, 2016, in Washington, D.C. It concentrated on screening and referrals to care, and on innovative financing for hepatitis C treatments.

NVHR’s Executive Director, Ryan Clary, spoke on the introductory panel at the beginning of the meeting. In his remarks, he stressed the importance of key barriers in the hepatitis B and C epidemics, including hepatitis C treatment access and the human impact of hepatitis B.

Click here for the agenda and presentations from the meeting.


Sponsors of the National Strategy for the Elimination of Hepatitis B & C